AMITRIPTYLINE-25 25 MG
AMITRIPTYLINE HYDROCHLORIDE : 25 MG · DIN 00371009 · PRO DOC LIMITEE
Health Canada status: MARKETED
What is AMITRIPTYLINE-25?
AMITRIPTYLINE-25 25 MG contains AMITRIPTYLINE HYDROCHLORIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 00371009, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Aug-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AMITRIPTYLINE-25 used for?
Drug management of depressive illness, including psychotic, endogenous, and neurotic depression. Alleviates anxiety component of depression.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00371009 |
|---|---|
| Brand name | AMITRIPTYLINE-25 |
| Generic / active ingredient | AMITRIPTYLINE HYDROCHLORIDE : 25 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AA09 AMITRIPTYLINE |
| AHFS class | 28:16.04.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Aug-2026 |
| Original market date | 1976-12-31 00:00:00 |
How is it administered?
Adults: 25 mg tid initially, up to 150 mg/day. Hospitalized: 100-200 mg/day. Elderly: Lower doses (e.g., 50 mg daily). Taper gradually when discontinuing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11). Standard practice is 15-30°C.
How is it supplied?
10 mg, 25 mg, 50 mg: Bottles of 100 and 1000 tablets. 75 mg: Bottles of 100 tablets.
Contraindications
Hypersensitivity; recent myocardial infarction; acute congestive heart failure; severe liver impairment; combination with cisapride or MAOIs (within 14 days).
Warnings and precautions
QT prolongation, arrhythmia, hypotension, suicide risk, Brugada syndrome, seizure disorder, urinary retention, glaucoma, thyroid disease. Impairs driving/machinery use.
What can be used instead?
Other Canadian products sharing ATC code N06AA09 AMITRIPTYLINE. 15 of 83 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMITRIPTYLINE-10 | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00370991 |
| AMITRIPTYLINE-50 | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00456349 |
| JAMP-AMITRIPTYLINE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02457679 |
| JAMP-AMITRIPTYLINE | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02457695 |
| JAMP-AMITRIPTYLINE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02457687 |
| JAMP-AMITRIPTYLINE | 75 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02457660 |
| MAR-AMITRIPTYLINE | 10 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02429861 |
| MAR-AMITRIPTYLINE | 25 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02429888 |
| MAR-AMITRIPTYLINE | 50 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02429896 |
| MAR-AMITRIPTYLINE | 75 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02429918 |
Who else supplies AMITRIPTYLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMITRIPTYLINE appears in 18 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.